The PennZone

  • Home
  • Health
  • Business
  • Non-profit
  • Technology
  • Music
  • Construction
  • Sports
  • Entertainment

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Dr. Curtis Rasmussen Shares Leadership and AI Insights on Lead Empowered TV
  • Lick Personal Oils Introduces the Ultimate Valentine's Day Gift Collection for Romantic, Thoughtful Gifting
  • Obey God Clothing Launches Urban Christian Apparel Line Serving All Ages
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
  • Breakout Phase for Public Company: New Partnerships, Zero Debt, and $20 Million Growth Capital Position Company for 2026 Acceleration
  • Japan's Patented "Hammock'n" Smartphone Band Targets Hand Fatigue From Long Phone Use
  • Reditus Group Introduces A New Empirical Model for Early-Stage B2B Growth
  • CCHR: Harvard Review Exposes Institutional Corruption in Global Mental Health

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Lineus Medical Completes UK Registration for SafeBreak® Vascular
  • Canyons & Chefs Announces Revamped Homepage
  • $140 to $145 Million in 2026 Projected and Profiled in New BD Deep Research Report on its Position in $57 Billion US Marine Industry; N Y S E: OTH
  • Really Cool Music Releases Its Fourth Single - "So Many Lost Years"
  • MGN Logistics Acquires Fast Service LLC, Fueling MyMGN Marketplace Expansion and Supercharging Expedited Coverage Nationwide
  • The Wait is Over: Salida Wine Festival Announces Triumphant 2026 Return After Seven-Year Hiatus
  • Graduates With $40K in Student Debt Are Buying Businesses Instead of Taking Entry-Level Jobs
  • Anne Seidman: Within the Lines
  • How Democrats Made Healthcare More Expensive in 2026
  • Inkdnylon Launches Bilingual Ask Inkdnylon Platform
  • JS Gallery Brings Global Voices to LA Art Show 2026 with "OFF SCRIPT" Exhibition
  • ANTOANETTA Partners With Zestacor Digital Marketing to Expand Online Presence for Handcrafted Luxury Jewelry
  • Mitchell Sipus Releases New Dance Single "Can U"
  • FrostSkin Launches Kickstarter Campaign for Patent-Pending Instant-Chill Water Purification Bottle
  • The New Monaco of the South (of Italy)
  • OctoNerv Completes Functional Prototype of Electronic Breast Nipple Implant (EBNI)
  • Zivra AI Launches Real-Time Business Health and Financial Intelligence for SMEs
  • Obey God Clothing Launches Urban Christian Apparel Line Serving All Ages
  • PA Golf Cart World Launches NEV Pre-Inspection & Compliance Service for 2026
  • Dr. Curtis Rasmussen Shares Leadership and AI Insights on Lead Empowered TV

Popular on PennZone

  • UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels - 219
  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026 - 201
  • Neurosurgeon Chengyuan Wu, MD, MSBmE, Joins the Actuated Medical Advisory Board
  • Twin Flame Visions Disrupts the Industry With Record Ad Performance and Rapid User Growth
  • SIMM Capital Fund Surpasses $25M Raised and $100M+ in Real Estate Assets
  • Bent Danholm Joins The American Dream TV as Central Florida Host
  • Children Rising Appoints Marshelle A. Wilburn as New Executive Director
  • NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB
  • Harry Hayman of Feed Philly Coalition Proudly Supports Sharing Excess' Holiday Food Rescue — Bri
  • God's Meal Barrel Combats the Increased Community Need in 2025

Similar on PennZone

  • AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
  • VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
  • Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
  • $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
  • U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
  • Global Innovators Take the Stage at the WorldUpstart Accelerator Showcase in Philadelphia
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us